To explore the mechanisms of PCa resistance to ARSIs, we analyzed RPS6KC1 expression in cells treated with Enzalutamide (Enz) or Darolutamide (Daro) using two transcriptomic datasets (GSE104935 and GSE148397) and a clinical PCa dataset (GSE70770). The gene discussed is RPS6KC1; the disease is posterior cortical atrophy.